APTANI2: update of aptamer selection through sequence-structure analysis

SUMMARY Here we present APTANI2, an expanded and optimized version of APTANI, a computational tool for selecting target-specific aptamers from HT-SELEX data through sequence-structure analysis. As compared to its original implementation, APTANI2 ranks aptamers and identifies relevant structural motifs through the calculation of a score that combines frequency and structural stability of each secondary structure predicted in any aptamer sequence. In addition, APTANI2 comprises modules for a deeper investigation of sequence motifs and secondary structures, a graphical user interface that enhances its usability, and coding solutions that improve performances. AVAILABILITY AND IMPLEMENTATION Source code, documentation, and example command lines can be downloaded from http://aptani.unimore.it. APTANI2 is implemented in Python 3.4, released under the GNU GPL3.0 License, and compatible with Linux, Mac OS and the MS Windows subsystem for Linux. SUPPLEMENTARY INFORMATION Supplementary information is available at Bioinformatics online.

[1]  Mark Sherman,et al.  Computational approaches in design of nucleic acid-based therapeutics. , 2018, Current opinion in biotechnology.

[2]  Silvio Bicciato,et al.  APTANI: a computational tool to select aptamers through sequence-structure motif analysis of HT-SELEX data , 2015, Bioinform..

[3]  S. Bicciato,et al.  A novel RNA aptamer identifies plasma membrane ATP synthase beta subunit as an early marker and therapeutic target in aggressive cancer , 2019, Breast Cancer Research and Treatment.

[4]  J. Tanner,et al.  G-quadruplex DNA aptamers and their ligands: structure, function and application. , 2012, Current pharmaceutical design.

[5]  Won Jun Kang,et al.  Gemcitabine-Incorporated G-Quadruplex Aptamer for Targeted Drug Delivery into Pancreas Cancer , 2018, Molecular therapy. Nucleic acids.

[6]  Rolf Backofen,et al.  AptaTRACE Elucidates RNA Sequence-Structure Motifs from Selection Trends in HT-SELEX Experiments. , 2016, Cell systems.

[7]  Yann Ponty,et al.  VARNA: Interactive drawing and editing of the RNA secondary structure , 2009, Bioinform..

[8]  J. Rossi,et al.  Aptamers as targeted therapeutics: current potential and challenges , 2016, Nature Reviews Drug Discovery.

[9]  Claudio Costantino,et al.  Pneumococcal Colonization in the Familial Context and Implications for Anti-Pneumococcal Immunization in Adults: Results from the BINOCOLO Project in Sicily , 2017, International journal of molecular sciences.

[10]  Teresa M. Przytycka,et al.  Identifying high-affinity aptamer ligands with defined cross-reactivity using high-throughput guided systematic evolution of ligands by exponential enrichment , 2015, Nucleic acids research.

[11]  Rolf Backofen,et al.  A Dynamic Programming Approach for Finding Common Patterns in RNAs , 2007, J. Comput. Biol..

[12]  Teresa M. Przytycka,et al.  Identification of sequence-structure RNA binding motifs for SELEX-derived aptamers , 2012, Bioinform..

[13]  P. Serafini,et al.  Aptamer-mediated blockade of IL4Rα triggers apoptosis of MDSCs and limits tumor progression. , 2012, Cancer research.

[14]  Ho Jin Sung,et al.  An RNA aptamer that specifically binds pancreatic adenocarcinoma up-regulated factor inhibits migration and growth of pancreatic cancer cells. , 2011, Cancer letters.

[15]  Rolf Backofen,et al.  AptaSUITE: A Full-Featured Bioinformatics Framework for the Comprehensive Analysis of Aptamers from HT-SELEX Experiments , 2018, Molecular therapy. Nucleic acids.